DP 103
Alternative Names: DP-103Latest Information Update: 08 Nov 2006
At a glance
- Originator D-Pharm
- Class
- Mechanism of Action Cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 27 Sep 2006 Discontinued - Preclinical for Alzheimer's disease in Israel (PO)
- 25 Oct 2002 This compound is still in active development
- 30 Oct 2001 Preclinical development for Alzheimer's disease in Israel (PO)